NCT02500576View on ClinicalTrials.gov

Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 7, 2015

Primary Completion Date

October 12, 2022

Study Completion Date

October 12, 2022

Conditions

Metastatic MelanomaStage IIIB Cutaneous Melanoma AJCC v7Stage IIIC Cutaneous Melanoma AJCC v7Stage IV Cutaneous Melanoma AJCC v6 and v7

Interventions

BIOLOGICAL

Aldesleukin

Given IV or SC

DRUG

Cyclophosphamide

Given IV

DRUG

Fludarabine Phosphate

Given IVPB

OTHER

Laboratory Biomarker Analysis

Correlative studies

BIOLOGICAL

Pembrolizumab

Given IV

OTHER

Quality-of-Life Assessment

Ancillary studies

BIOLOGICAL

Therapeutic Tumor Infiltrating Lymphocytes

Given IV

Trial Locations (1)

77030

M D Anderson Cancer Center, Houston

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

M.D. Anderson Cancer Center

OTHER

NCT02500576 - Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma | Biotech Hunter | Biotech Hunter